Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | CNR2 | P34972 | 2/20 | 0.59 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.51 |
| ▸ | WNT3A | P56704 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28815055 | 0.98 | LMNA (0.62) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL3186240 | 0.88 | LMNA (0.53) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL8989958 | 0.88 | GAA (0.53) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL3717986 | 0.87 | GAA (0.56) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL31369140 | 0.87 | GAA (0.56) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL3186249 | 0.87 | LMNA (0.51) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL28634751 | 0.86 | LMNA (0.64) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL11459852 | 0.85 | RORC (0.51) | LMNAGAACNR2SMN1; SMN2MAPK14 | |
| SCHEMBL221518 | 0.84 | LMNA (0.62) | LMNAGAACNR2CTNNB1WNT3A | |
| SCHEMBL2195147 | 0.84 | LMNA (0.62) | LMNAGAACNR2CTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113429338-B | Method for synthesizing fluopyram | 陕西泰合利华工业有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-113429338-A | Method for synthesizing fluopyram | 陕西泰合利华工业有限公司 | 2021-09-24 | — | — | CN | claimed |
| CN-107108630-B | Substituted N- (pyrrolidin-3-yl) -7H-pyrrolo [2,3-D ] pyrimidin-4-amines as JANUS kinase inhibitors | 阳智化学（株） | 2019-10-15 | — | — | CN | claimed |
| CN-107108630-A | Substituted N- (pyrrolidin-3-yl) -7H-pyrrolo [2,3-D ] pyrimidin-4-amines as JANUS kinase inhibitors | 阳智化学（株） | 2017-08-29 | — | — | CN | claimed |
| CN-104119285-B | Compound and application thereof as estrogen-related receptor modulator | 中国科学院广州生物医药与健康研究院 | 2016-06-29 | — | — | CN | claimed |
| CN-104119285-A | Compound used as estrogen-related receptor regulator and application of compound | GUANGZHOU INST BIOMED & HEALTH | 2014-10-29 | — | — | CN | claimed |
| WO-2008140810-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-11-20 | — | — | WO | claimed |
| CN-101083994-A | Heterocyclic derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2007-12-05 | — | — | CN | claimed |
| CN-1822828-A | Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments | JANSSEN PHARMACEUTICA NV (BE) | 2006-08-23 | — | — | CN | claimed |
| US-5017730-A | Process of preparing bis (trifluoromethylphenyl) methanol | CENTRAL GLASS COMPANY, LIMITED (JP) | 1991-05-21 | — | — | US | claimed |
| US-12351857-B2 | Activity based probes | UNIVERSITY OF DUNDEE (GB) | 2025-07-08 | — | — | US | disclosed |
| WO-2025109600-A1 | PROCESS FOR PREPARATION OF SULFONYL PYRAZOLONES | ADAMA AGAN LTD. (IL) | 2025-05-30 | — | — | WO | disclosed |
| EP-3981754-B1 | METHOD FOR MANUFACTURING 1-HALO-2-FLUOROETHYLENE | DAIKIN IND LTD (JP) | 2024-11-06 | — | — | EP | disclosed |
| US-12054445-B2 | Method for manufacturing 1-halo-2-fluoroethylene | DAIKIN INDUSTRIES, LTD. (JP) | 2024-08-06 | — | — | US | disclosed |
| CN-114057559-B | Preparation method of diaryl ketone | 中南民族大学 | 2023-10-03 | — | — | CN | disclosed |
| US-5051520-A | Chemical intermediates for polymers such as polyimides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-09-24 | — | — | US | disclosed |
| US-5017730-A | Process of preparing bis (trifluoromethylphenyl) methanol | CENTRAL GLASS COMPANY, LIMITED (JP) | 1991-05-21 | — | — | US | disclosed |
| US-5017730-A | Process of preparing bis (trifluoromethylphenyl) methanol | CENTRAL GLASS COMPANY, LIMITED (JP) | 1991-05-21 | — | — | US | disclosed |
| US-4975438-A | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. (US) | 1990-12-04 | — | — | US | disclosed |
| US-4788206-A | CARDIOVASCULAR DISORDERS, PLATELETS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054445-B2 | Method for manufacturing 1-halo-2-fluoroethylene | COPE, FUCA2, RER1 | LMNA 2865/4885GAA 1475/4885CNR2 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.